Inspire Investing LLC Has $2.29 Million Stake in Chemed Corporation $CHE

12 Sep 2025, 12:05 by Mitch Edgeman · The Markets Daily

Inspire Investing LLC trimmed its stake in shares of Chemed Corporation (NYSE:CHE – Free Report) by 31.4% during the first quarter, Holdings Channel.com reports. The firm owned 3,721 shares of the company’s stock after selling 1,700 shares during the period. Inspire Investing LLC’s holdings in Chemed were worth $2,290,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. GAMMA Investing LLC lifted its holdings in Chemed by 131,200.8% in the first quarter. GAMMA Investing LLC now owns 166,752 shares of the company’s stock valued at $102,606,000 after buying an additional 166,625 shares during the period. Point72 Asset Management L.P. acquired a new position in Chemed in the fourth quarter valued at approximately $54,587,000. Fuller & Thaler Asset Management Inc. lifted its holdings in Chemed by 249.3% in the first quarter. Fuller & Thaler Asset Management Inc. now owns 130,037 shares of the company’s stock valued at $80,015,000 after buying an additional 92,813 shares during the period. Woodline Partners LP lifted its holdings in Chemed by 2,681.0% in the first quarter. Woodline Partners LP now owns 58,178 shares of the company’s stock valued at $35,798,000 after buying an additional 56,086 shares during the period. Finally, Nuveen LLC acquired a new position in Chemed in the first quarter valued at approximately $30,527,000. 95.85% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Chemed

In related news, Director George J. Walsh III acquired 200 shares of the company’s stock in a transaction that occurred on Monday, August 4th. The shares were acquired at an average cost of $417.10 per share, for a total transaction of $83,420.00. Following the completion of the acquisition, the director directly owned 3,523 shares in the company, valued at approximately $1,469,443.30. The trade was a 6.02% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Nicholas Michael Westfall sold 10,012 shares of the firm’s stock in a transaction on Monday, August 4th. The stock was sold at an average price of $421.91, for a total transaction of $4,224,162.92. The disclosure for this sale can be found here. 3.29% of the stock is owned by insiders.

Chemed Stock Performance

CHE opened at $457.85 on Friday. The firm’s fifty day moving average is $452.36 and its two-hundred day moving average is $531.77. The firm has a market cap of $6.67 billion, a PE ratio of 23.54, a price-to-earnings-growth ratio of 2.48 and a beta of 0.46. Chemed Corporation has a twelve month low of $408.42 and a twelve month high of $623.60.

Chemed (NYSE:CHE – Get Free Report) last posted its earnings results on Tuesday, July 29th. The company reported $4.27 earnings per share for the quarter, missing the consensus estimate of $6.02 by ($1.75). The firm had revenue of $618.80 million during the quarter, compared to analyst estimates of $650.60 million. Chemed had a return on equity of 25.83% and a net margin of 11.56%.The company’s revenue for the quarter was up 3.8% on a year-over-year basis. During the same quarter last year, the business posted $5.47 earnings per share. Chemed has set its FY 2025 guidance at 22.000-22.300 EPS. Equities analysts forecast that Chemed Corporation will post 21.43 EPS for the current fiscal year.

Chemed Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, August 29th. Shareholders of record on Monday, August 11th were issued a $0.60 dividend. This represents a $2.40 annualized dividend and a yield of 0.5%. This is a boost from Chemed’s previous quarterly dividend of $0.50. The ex-dividend date was Monday, August 11th. Chemed’s dividend payout ratio (DPR) is 12.34%.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the stock. Oppenheimer cut their price objective on shares of Chemed from $650.00 to $580.00 and set an “outperform” rating on the stock in a report on Thursday, July 31st. Jefferies Financial Group upgraded shares of Chemed from a “hold” rating to a “buy” rating and increased their price objective for the company from $490.00 to $550.00 in a report on Tuesday, September 2nd. Bank of America cut their price objective on shares of Chemed from $610.00 to $595.00 and set a “buy” rating on the stock in a report on Wednesday. Royal Bank Of Canada cut their price objective on shares of Chemed from $640.00 to $589.00 and set an “outperform” rating on the stock in a report on Thursday, July 31st. Finally, Wall Street Zen lowered shares of Chemed from a “buy” rating to a “hold” rating in a report on Saturday, July 5th. Four equities research analysts have rated the stock with a Buy rating, According to MarketBeat.com, Chemed currently has an average rating of “Buy” and an average price target of $578.50.

View Our Latest Stock Analysis on Chemed

About Chemed

(Free Report)

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.